Literature DB >> 11069216

Limited sampling strategies.

O David, A Johnston.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 11069216     DOI： 10.2165/00003088-200039040-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  10 in total

1.  New approaches to cyclosporine monitoring raise further concerns about analytical techniques.

Authors:  D W Holt; A Johnston; B D Kahan; R G Morris; M Oellerich; L M Shaw
Journal:  Clin Chem       Date:  2000-06       Impact factor: 8.327

2.  Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Technical note.

Authors:  F Gaspari; N Perico; O Signorini; R Caruso; G Remuzzi
Journal:  Kidney Int       Date:  1998-12       Impact factor: 10.612

3.  Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.

Authors:  A Serafinowicz; Z Gaciong; T Baçzkowska; K Rell; M Lao; J Wałaszewski
Journal:  Transplant Proc       Date:  1996-12       Impact factor: 1.066

4.  Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral.

Authors:  A Serafinowicz; Z Gaciong; J Majchrzak; T Baczkowska; E Nowacka; L Gradowska; W Rowiński; M Lao
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

5.  A limited sampling strategy for the measurement of cyclosporine AUC.

Authors:  A Johnston; I Sketris; J T Marsden; C G Galustian; T Fashola; D Taube; J Pepper; D W Holt
Journal:  Transplant Proc       Date:  1990-06       Impact factor: 1.066

6.  Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration.

Authors:  F Gaspari; M F Anedda; O Signorini; G Remuzzi; N Perico
Journal:  J Am Soc Nephrol       Date:  1997-04       Impact factor: 10.121

7.  A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients.

Authors:  H U Meier-Kriesche; R Alloway; A O Gaber; D M Canafax; B Kaplan
Journal:  J Clin Pharmacol       Date:  1999-02       Impact factor: 3.126

Review 8.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

9.  A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.

Authors:  P Keown; D Landsberg; P Halloran; A Shoker; D Rush; J Jeffery; D Russell; C Stiller; N Muirhead; E Cole; L Paul; J Zaltzman; R Loertscher; P Daloze; R Dandavino; A Boucher; P Handa; J Lawen; P Belitsky; P Parfrey
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

10.  Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.

Authors:  B D Kahan; J Dunn; C Fitts; D Van Buren; D Wombolt; R Pollak; R Carson; J W Alexander; M Choc; R Wong
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939
  10 in total
  2 in total

1.  Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.

Authors:  Eileen B Lawson; Jerry C Wu; R Michael Baldwin; Magnus Ingelman-Sundberg; Staffan Rosenborg; Dong-Seok Yim; Ophelia Q P Yin; Edmund V Capparelli; Joseph D Ma
Journal:  Eur J Clin Pharmacol       Date:  2011-10-19       Impact factor: 2.953

2.  Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.

Authors:  Hélène Bourgoin; Gilles Paintaud; Matthias Büchler; Yvon Lebranchu; Elisabeth Autret-Leca; France Mentré; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.